At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
Ensartinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1, Dose-escalating, Open-label Study of Ensartinib, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
In Brief
A Phase 1 clinical trial evaluating Ensartinib for Solid Tumor and Non-Small Cell Lung Cancer Metastatic. Completed, enrolled 48 participants across 1 site.
Detailed Summary
This study is aimed to determine the maximum tolerated dose of ensartinib, an oral ALK inhibitor in Chinese patients with ALK-positive non-small cell lung cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Non-Small Cell Lung Cancer Metastatic
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartMar 2017
Primary CompletionOct 2019
Study CompletionApr 2020
TodayJul 2026
First PostedNov 9, 2016
Enrollment StartMar 6, 2017
Primary CompletionOct 31, 2019
Study CompletionApr 23, 2020
TodayJul 1, 2026
Enrollment to primary: 2.7 yearsPosted 9.6 years ago
Interventions
Ensartinibdrug
Oral ensartinib was given daily at escalating doses in a 28-day cycle